European public procurement and grants data from official registers · Data as of 18 November 2026; updated daily.

Tenders

Cardiovascular drug tenders in Czechia

Cardiovascular drug tenders in Czechia: 506 listed on GranTender since 2024; 9 open now. The median awarded contract value is about €330,000 (796 contracts with a stated value). Buyers with the most tenders: Fakultní nemocnice Olomouc (87), Institut klinické a experimentální medicíny (65) and Fakultní nemocnice Ostrava (42); suppliers with the most contract awards: Takeda Pharmaceuticals Czech Republic s.r.o. (61), ViaPharma s.r.o. (41) and Amgen s.r.o. (34). Sources: Registr smluv, ISVZ (NIPEZ) and TED. In 2025 the median contract value was €290,000; 48% of contracts drew a single bid (13.3 bids on average). Data as of 18 November 2026; updated daily.

Tenders
506
Open tenders
9
Awards
1,349
Awarded value awarded
€1,213,141,738
Awarded value contract
€164,571,379
Awarded value framework ceiling
€101,359,759
Median contract value awarded
≈ €330,000
Median contract value contract
≈ €260,000
Median contract value framework ceiling
≈ €240,000
Average bids per contract
12.6
Tenders in 2025
173 +2% on 2024

Median: contracts with a stated value, rounded. Average bids: contracts where the number of bids is published.

Value kinds: awarded — the value in the award decision; contract — the value of the signed or amended contract; paid — the amount actually paid; framework ceiling — the maximum of a framework agreement, given with every winner, not money spent. Different kinds are never added together.

Open tenders

TenderBuyerEstimated valueStatusPublished
Dodávky léčivého přípravku s účinnou látkou CangrelorumFakultní nemocnice OstravaCZK 13,596,132 (≈ €559,604)Open13 November 2026
Heparinum natricum II.Institut klinické a experimentální medicínyCZK 41,786,000 (≈ €1,719,872)Open11 November 2026
Kardiaka 16 - AmiodaronInstitut klinické a experimentální medicínyCZK 573,000 (≈ €23,584)Open10 November 2026
LP s obsahem vutrisiranu 2026Fakultní nemocnice OlomoucCZK 24,896,495 (≈ €1,024,716)Open30 October 2026
LP s obsahem vutrisiranu 2026Fakultní nemocnice OlomoucCZK 24,896,495 (≈ €1,024,716)Open30 October 2026
ANTITROMBIN III 2026Fakultní nemocnice OlomoucCZK 20,810,648 (≈ €856,546)Open16 October 2026
ANTITROMBIN III 2026Fakultní nemocnice OlomoucCZK 20,810,648 (≈ €856,546)Open16 October 2026
Antikoagulační roztok 4% citronanu sodnéhoFakultní nemocnice Hradec KrálovéCZK 2,695,000 (≈ €110,924)Open6 October 2026
Antikoagulační roztok 4% citronanu sodnéhoFakultní nemocnice Hradec KrálovéCZK 2,695,000 (≈ €110,924)Open6 October 2026

Latest tenders

TenderBuyerEstimated valueStatusPublished
Dodávky léčivého přípravku s účinnou látkou CangrelorumFakultní nemocnice OstravaCZK 13,596,132 (≈ €559,604)Open13 November 2026
Heparinum natricum II.Institut klinické a experimentální medicínyCZK 41,786,000 (≈ €1,719,872)Open11 November 2026
Kardiaka 16 - AmiodaronInstitut klinické a experimentální medicínyCZK 573,000 (≈ €23,584)Open10 November 2026
LP s obsahem vutrisiranu 2026Fakultní nemocnice OlomoucCZK 24,896,495 (≈ €1,024,716)Open30 October 2026
LP s obsahem vutrisiranu 2026Fakultní nemocnice OlomoucCZK 24,896,495 (≈ €1,024,716)Open30 October 2026
ANTITROMBIN III 2026Fakultní nemocnice OlomoucCZK 20,810,648 (≈ €856,546)Open16 October 2026
ANTITROMBIN III 2026Fakultní nemocnice OlomoucCZK 20,810,648 (≈ €856,546)Open16 October 2026
Léčivé přípravky s obsahem romiplostimuFakultní nemocnice Hradec KrálovéCZK 8,538,000 (≈ €351,416)Closed9 October 2026
Léčivé přípravky s obsahem romiplostimuFakultní nemocnice Hradec KrálovéCZK 8,538,000 (≈ €351,416)Closed9 October 2026
Antikoagulační roztok 4% citronanu sodnéhoFakultní nemocnice Hradec KrálovéCZK 2,695,000 (≈ €110,924)Open6 October 2026
Antikoagulační roztok 4% citronanu sodnéhoFakultní nemocnice Hradec KrálovéCZK 2,695,000 (≈ €110,924)Open6 October 2026
Léčivé přípravky s obsahem mitapivátuFakultní nemocnice Hradec KrálovéCZK 106,500,000 (≈ €4,383,438)Closed29 September 2026
Léčivé přípravky s obsahem mitapivátuFakultní nemocnice Hradec KrálovéCZK 106,500,000 (≈ €4,383,438)Closed29 September 2026
Léčivé přípravky pro krev - kombinace koagulačních faktorů V.Institut klinické a experimentální medicínyCZK 12,714,000 (≈ €523,296)Closed25 September 2026
LP pro krev - kombinace koagulačních faktorů V.Institut klinické a experimentální medicínyCZK 12,714,000 (≈ €523,296)Closed24 September 2026
Léčivé přípravky s obsahem rosuvastatinu, fenofibrátu, ezetimibu, kyseliny bempedoové, sodné soli olezarsenuFakultní nemocnice Hradec Králové—Closed23 September 2026
Léčivé přípravky s obsahem rosuvastatinu, fenofibrátu, ezetimibu, kyseliny bempedoové, sodné soli olezarsenuFakultní nemocnice Hradec Králové—Closed23 September 2026
Dodávky léků – Léčivá látka enoxaparin – ATC B01AB05Fakultní Thomayerova nemocniceCZK 54,879,048 (≈ €2,258,769)Closed22 September 2026
Kardiaka 15 - AcoramidisInstitut klinické a experimentální medicínyCZK 256,400,000 (≈ €10,553,177)Closed17 September 2026
Antihemoragika 2026 - komplex koagulačních faktorů IX, II, VII a XFakultní nemocnice Hradec KrálovéCZK 24,356,400 (≈ €1,002,486)Closed17 September 2026

Competition and prices

In 2025, half of the contracts were worth between €55,000 and €1.2 million, with a median of €290,000 (326 contracts with a stated awarded value). Contracts drew 13.3 bids on average (median 2) and 48% drew a single bid — based on 502 contracts with a known number of bids. Compared with 2024, in 2025 the median value fell 15% and the share of single-bid contracts fell from 50% to 48%. The usual procedures: open procedure (79%), other procedures (18%), restricted procedure (2%) — of 392 tenders with a stated procedure.

The most contracts went to Takeda Pharmaceuticals Czech Republic s.r.o. (61), ViaPharma s.r.o. (41) and Amgen s.r.o. (34) — together 10% of all contracts.

YearContractsMedian valueMiddle half of valuesBids on averageSingle bid
2024438€340,000€82,000 – €1.3 million10.350% (306)
2025540€290,000€55,000 – €1.2 million13.348% (502)
2026 (so far)322€340,000€58,000 – €1.6 million14.237% (288)
All years1,321€330,000€58,000 – €1.3 million12.645% (1,109)

Values: contracts with a stated value in EUR, each value kind on its own (awarded or contract value), approximate (±3 %). Bids: contracts of procedures with competition whose number of bids the source publishes (1–100 bids); the sources publish it for some contracts only (TED ≈ 3 in 4, Spain all, Poland about half, Italy few), so each figure states its base and is shown from 20 contracts. A contract counts in the year of its award (else of its tender). Figures as of 13 November 2026, recomputed every week.

Where you have a chance

Since 1 November 2024, 44% of the 857 contracts with a known number of bids had a single bid; the median was 2 bids. The number of bids is known for 857 of the 929 contracts from procedures with competition.

Buyers who often get few offers

The buyers below usually received one or two offers per contract — an offer from you would stand out.

In the last 12 months, 0 companies won their first contract in our records here — 0% of the 115 contracts (our records start on 1 January 2024).

Contracts awarded since 1 November 2024 (the last 24 months). Bids as the source publishes them, 1 to 100 per contract, in procedures with competition only (a direct award has one offer by design). As of 13 November 2026.

Main CPV divisions

CPV codes of this topic

  • 33620000 Medicinal products for the blood, blood-forming organs and the cardiovascular system

A tender belongs here when its main CPV code starts with one of these codes; a tender without a usable CPV code (or with a general one) is matched by words of its title. A tender may belong to up to three topics.

Cardiovascular and anticoagulant drugs in neighbouring countries

Today, 8 tenders in the same niche are open in neighbouring countries.

Public tenders in the EU and the EEA are open to companies from every EU and EEA country on the same terms as local ones, and to companies from countries with a procurement agreement with the EU (such as Switzerland, the United Kingdom and Ukraine) for the contracts it covers. Open means the deadline has not passed (today's date). Neighbours: countries with a land border, a fixed link or a short sea crossing.

Expected soon1

ExpectedBuyerWhatWhy we expect itConfidence
now – Nov 2026
every year
Krajská nemocnice Liberec, a.s.Cardiovascular and anticoagulant drugs
Léčivé přípravky s obsahem účinné látky EVOLOKUMAB
Typical value: ≈ €790,000
The buyer has published cardiovascular drug tenders every year in November since 2024.
Earlier tenders: 10/2025, 11/2024
medium

Forecast from public data, not an announcement. Methodology.

Market reports

Cardiovascular and anticoagulant drugs by city

Cardiovascular and anticoagulant drugs in other countries

Cardiovascular and anticoagulant drugs across Europe

Topics in Health, medical equipment and medicines

Questions and answers

Which cardiovascular drug tenders in Czechia are open now?
9 of the 506 cardiovascular drug tenders in Czechia listed on GranTender are open for bids. For example: Dodávky léčivého přípravku s účinnou látkou Cangrelorum; Heparinum natricum II.; Kardiaka 16 - Amiodaron.
Where can I find cardiovascular drug tenders in Czechia?
GranTender lists them in one place, from Registr smluv, ISVZ (NIPEZ) and TED, with their buyers, winners and contract values; 9 are open now. Search in one country at a time (the first 5 results) is free; search across all countries at once, full result lists, saved keywords with an e-mail once a week and exports come with a plan.
Who wins the most cardiovascular drug tenders in Czechia?
By number of contracts won: Takeda Pharmaceuticals Czech Republic s.r.o. (61), ViaPharma s.r.o. (41), Amgen s.r.o. (34).
Which buyers publish the most cardiovascular drug tenders in Czechia?
By number of tenders: Fakultní nemocnice Olomouc (87), Institut klinické a experimentální medicíny (65), Fakultní nemocnice Ostrava (42).
Which CPV codes belong to “Cardiovascular and anticoagulant drugs”?
33620000 Medicinal products for the blood, blood-forming organs and the cardiovascular system; plus tenders without a usable CPV code whose title names the topic.
How many bids do cardiovascular drug tenders in Czechia receive on average?
In 2025, contracts drew 13.3 bids on average (median 2) and 48% drew a single bid — based on 502 contracts with a known number of bids.
How much are contracts for cardiovascular drug tenders in Czechia worth?
In 2025, half of the contracts were worth between €55,000 and €1.2 million, with a median of €290,000 (326 contracts with a stated awarded value). Compared with 2024, in 2025 the median value fell 15% and the share of single-bid contracts fell from 50% to 48%.
Which procedures are used for cardiovascular drug tenders in Czechia?
The usual procedures: open procedure (79%), other procedures (18%), restricted procedure (2%) — of 392 tenders with a stated procedure.
Which buyers get few offers in cardiovascular drug tenders in Czechia?
Since 1 November 2024, these buyers usually received one or two offers per contract: Fakultní nemocnice Olomouc (median 1 bid over 82 contracts), Institut klinické a experimentální medicíny (median 1 bid over 94 contracts) and Krajská nemocnice Liberec, a.s. (median 1 bid over 6 contracts). Since 1 November 2024, 44% of the 857 contracts with a known number of bids had a single bid; the median was 2 bids.

CPV 2008 (Regulation (EC) No 213/2008), © European Union, Publications Office — via the eForms SDK, CC BY 4.0.